Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus. To STING
Things have just gone from bad to worse at Hopkinton, MA-based Spring Bank Pharmaceuticals.
Researchers say that a patient died in their Phase IIb study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
